OBI-1's force no longer with Inspiration and Ipsen as hemophilia asset goes over to Baxter
This article was originally published in Scrip
With the sale of OBI-1 (recombinant porcine Factor VIII) to Baxter International for potentially more than $700 million and with the disposition of IB1001 (intravenous recombinant Factor IX) on the horizon, Inspiration Biopharmaceuticals has just months left before the hemophilia-focused company winds down operations after filing for Chapter 11 bankruptcy protection at the end of October (scripintelligence.com, 1 November 2012).
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.